Cost and access barriers shaping how people use GLP-1 drugs is a sobering read. Good reminder that even a carefully designed treatment runs into the real-world interface of affordability. https://arstechnica.com/health/2026/11/millions-in-us-use-unapproved-glp-1s-and-use-them-in-unapproved-ways/By Tess, Nov 14, 2026. 2 likes, 0 comments.